關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

WAT Medical Sponsors American Headache Society 2024 Scottsdale Headache Symposium

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 99 加入收藏 :

VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- WAT Medical Enterprise proudly sponsored the 2024 Scottsdale Headache Symposium, organized by the American Headache Society from November 14-17 in Scottsdale, AZ. This annual event brought together a multidisciplinary audience of neurologists, general practitioners, pediatricians, anesthesiologists, psychologists, and other healthcare providers. The symposium featured diverse educational formats, including lectures, case studies, panel discussions, and hands-on demonstrations, offering cutting-edge insights into headache diagnosis and treatment.

One of the highlights of the event was the HeadaTerm 2, a newly developed neuromodulation device that garnered significant attention for its innovative design, ease of use, and competitive pricing. HeadaTerm 2 utilizes external trigeminal nerve stimulation and is FDA-cleared for the preventive treatment of migraines. Clinical studies indicate that it can be up to 35% more effective than oral NSAIDs in managing acute migraine episodes, underscoring its potential to transform headache care.

Additionally, WAT Medical showcased EmeTerm, an FDA-cleared anti-nausea wristband designed to alleviate nausea and vomiting often associated with migraines. The drug-free wristband, highly rated by consumers and clinicians, is a top-selling product on Amazon and widely endorsed by medical professionals across North America.

By collaborating with influential organizations such as the American Headache Society and the American Migraine Foundation, WAT Medical continues its commitment to advancing migraine treatment through groundbreaking neuromodulation technologies, aiming to enhance patient outcomes and improve quality of life.

References:

[1]Hokenek N M, Erdogan M O, Hokenek U D, et al. Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomize controlled trial[J]. The American Journal of Emergency Medicine, 2021, 39: 80-85.
[2]www.americanheadachesociety.org 
[3]www.watmedical.com
[4]www.emeterm.com

以上新聞投稿內容由 PR Newswire 美通社 全權自負責任,若有涉及任何違反法令、違反本網站會員條款、有侵害第三人權益之虞,將一概由 PR Newswire 美通社 承擔法律及損害賠償之責任,與台灣產經新聞網無關。

Tags :
2025 年 1 月 21 日 (星期二) 農曆十二月廿二日
首 頁 我的收藏 搜 尋 新聞發佈